Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra’s co-Founder Nicholas Benedict also participated in the round. Allecra will use the proceeds for
Kamada and Baxalta (formerly Baxter International’s BioScience business and now part of Shire) entered into a cooperation agreement in 2010 for the distribution and license of Glassia, which
HT-1 is a rare genetic disease in infants and children. It could lead to liver and kidney complications and become fatal if not treated. Orfadin is indicated as
Under the deal, Clinigen’s Idis Global Access (GA) division will make the drug available on request in 20 European countries as well as Australia, New Zealand and Hong
Gonitro is available in single-dose packets of a short-acting nitrate in a stabilized crystal granule form. Each Gonitro packet contains 400 mcg of nitroglycerin. The clinical data suggests
Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. It has fast track status, orphan drug designation and rare pediatric disease designation for DMD. One of the pivotal
Three-month follow-up data is anticipated to be available in the fourth quarter of this year. The company started the regulatory process for a phase II/III clinical trial for
In both studies, MK-1293 demonstrated non-inferiority in change from baseline A1C (a measure of average blood glucose) and similar safety to Lantus (insulin glargine) after 24 weeks. The
SHP621 (budesonide oral suspension) is in phase 3 development for the treatment of eosinophilic esophagitis (EoE). EoE is a severe, chronic and rare disease that stems from an
It has approved the application for dolutegravier 10 milligram and 25 milligram oral tablets, reducing the weight limit to at least 30 kilograms from at least 40 kilograms,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.